Development of active safety surveillance system for traditional Chinese medicine: an empirical study in treating climacteric women.
OBJECTIVE
Traditional Chinese medicines (TCM) prescribed by doctors are regularly reimbursed by the National Health Insurance (NHI) in Taiwan. The safety of TCM should undergo the same scrutiny that most western medicines do. This study was to monitor adverse events (AEs) associated with a new mixture of TCM, TMN-1, used to treat climacteric symptoms.


METHODS
For this multi-center, prospective observational study, we recruited 134 women with climacteric symptoms. During this 12-week study, the subjects made nine visits, took TMN-1 three times a day, and received routine hematologic tests, biochemical tests, and tests for gynecologically relevant hormones at baseline and after 4 and 12 weeks of beginning medication. At every visit, the subjects were asked by questionnaire about any AEs. All AEs were examined through a process of causality assessment (CA) by a research team.


RESULTS
In total, we recorded 203 AEs, in order of decreasing incidences--cough, pharyngitis, rhinitis, abdominal pain, abdominal fullness, diarrhea, and pruritus with incidence rates of 2.57, 2.47, 1.88, 1.78, 1.68, 1.58, and 1.58 per 10(3) person-days, respectively. Most AEs were tolerable. Five of the AEs were judged to be "probable" adverse drug reactions (ADRs): Two events of diarrhea and one event each of nausea, abdominal pain, and abdominal fullness.


CONCLUSIONS
This study demonstrates the effectiveness using active safety surveillance to document safety of TCMs. This surveillance system could probably be useful to document the safety of other alternative or complementary medicines.
Hsieh
Shu-Ching
SC
Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan.
Lai
Jung-Nien
JN
Chen
Pau-Chung
PC
Chen
Huey-Jen
HJ
Wang
Jung-Der
JD
D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D004365:Drugs, Chinese Herbal / Q000009:adverse effects; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D008516:Medicine, Chinese Traditional / Q000009:adverse effects* / Q000592:standards*; D009726:Nurses; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D013624:Taiwan
D004365:Drugs, Chinese Herbal; D006728:Hormones